title: Induction chemotherapy in advanced head and neck cancer. Preliminary results of a randomized study.
abstract: From March 1983 to June 1986, 100 patients with locally advanced squamous cell carcinoma of the head and neck were randomized to receive either two courses of chemotherapy prior to local therapy (group A), or local therapy alone (group B). Local treatment consisted of primary radiotherapy in all patients. When a poor response was observed after 55 Gy, surgery was performed. The chemotherapy regimen was a combination of cisplatinum, bleomycin, vindesine, and mitomycin C. The response rate to induction chemotherapy (group A) was 50% for the primary tumor (CR: 10% and PR: 40%). At the end of radiotherapy, the overall tumor response rates in the two groups A and B, were 77% and 79% respectively. Complete disappearance of the primary tumor occurred more often than that of the lymph node metastases. The response rate to induction chemotherapy for lymph node metastases was 27.1% (CR: 9% and PR: 18.1%). An initial major response to chemotherapy predicted subsequent efficacy of irradiation on 90% of the cases, while a failure of chemotherapy had no predictive value in this respect. The survival rates in groups A and B were 66.5% vs. 65.1% at 1 year and 35% vs. 46.2% at 2 years. Local disease-free and disease-free intervals were similar in both groups. A Cox's multi-step regression analysis revealed two significant independant prognostic factors: size of primary tumor and nodal status. After adjustment for these factors, the chemotherapy did not seem to improve the effectiveness of the local treatment in terms of loco-regional control and survival.
authors.affiliation: Department of Radiotherapy, Curie Institute, Paris, France.
authors.forename: F
authors.initials: F
authors.lastname: Brunin
authors.forename: J
authors.initials: J
authors.lastname: Rodriguez
authors.forename: C
authors.initials: C
authors.lastname: Jaulerry
authors.forename: M
authors.initials: M
authors.lastname: Jouve
authors.forename: D
authors.initials: D
authors.lastname: Pontvert
authors.forename: D
authors.initials: D
authors.lastname: Point
authors.forename: V
authors.initials: V
authors.lastname: Mosseri
authors.forename: P
authors.initials: P
authors.lastname: Pouillart
authors.forename: B
authors.initials: B
authors.lastname: Asselain
authors.forename: J
authors.initials: J
authors.lastname: Brugere
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D009367:Neoplasm Staging; D011897:Random Allocation; D012074:Remission Induction